Drug Profile
ZT 01
Alternative Names: ZT-01Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Tulane University; University of Toronto; York University
- Developer Zucara Therapeutics
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Somatostatin receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypoglycaemia
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Hypoglycaemia(Prevention) in Canada (SC, Injection)
- 02 Oct 2023 Updated efficacy data from a phase Ib trial in Hypoglycaemia presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 28 Jul 2023 Phase-II clinical trials in Hypoglycaemia (Prevention) in USA (SC) (NCT05762107)